CLINICAL_TRIALS
trial_result
· 2022-09-01
Clinical Trial Update: A Safety Study Comparing LY2140023 to Atypical Antipsychotic Standard Treatment in Schizophrenic Patients [Phase 2]
Summary
A Phase 2 safety trial comparing LY2140023 to standard atypical antipsychotic treatment in schizophrenia has completed with posted results.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Denovo Biopharma LLC | Conditions: Schizophrenia | Phase 2 | Status: COMPLETED | Results posted: 2022-09-01